Nucleotide analogs as novel anti-hepatitis B virus agents

Authors

P. I. Radhakrishnan
S. P.
G. Z.
John D. Morrey, Utah State UniversityFollow
B. E. Korba

Document Type

Article

Journal/Book Title/Conference

Current Opinions in Pharmacology

Volume

5

Publication Date

2005

First Page

520

Last Page

528

Abstract

During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di-and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.

Recommended Citation

Radhakrishnan, P.I., S.P., G.Z., J.D. Morrey, and B.E. Korba 2005. Nucleotide analogs as novel anti-hepatitis B virus agents. Current Opinions in Pharmacology 5: 520-528.